Sutter Davis Hospital CEO Janet Wagner to Succeed Retiring Bob Merwin
Janet Wagner, chief executive officer of Sutter Davis Hospital, has been named the next CEO for Mills-Peninsula Health Services. She will be only the fourth CEO at Mills-Peninsula in its 60-year history. Wagner succeeds current Mills-Peninsula CEO Bob Merwin who has led the organization for 27 years. Wagner begins her new role on September 29 and will work closely with Merwin to ensure a smooth transition upon his retirement in January 2015.
“I am very proud that we are able to tap talent like Janet Wagner’s from within the Sutter Health family to grow and take on new leadership roles. This is especially important as we continue on the path to become a truly integrated health care organization, linking and strengthening local, regional and system-wide strategies and services to keep our patients at the center of everything we do,” said Jeff Gerard, Sutter Health regional president.
Designed to rate how well hospitals protect patients from accidents, errors, injuries and infections, the latest Hospital Safety Score honored Mills-Peninsula with an “A,” its top grade in patient safety. The Hospital Safety Score is compiled under the guidance of the nation’s leading experts on patient safety and is administered by The Leapfrog Group (Leapfrog), an independent industry watchdog. The first and only hospital safety rating to be peer-reviewed in the Journal of Patient Safety, the Score is free to the public and designed to give consumers information they can use to protect themselves and their families when facing a hospital stay. Read More about Mills-Peninsula Earns ‘A’ Grade in Spring 2014 Hospital Safety Score
This week Google announced its latest innovation: a smart contact lens developed to help people with diabetes monitor their glucose levels. Patients are more likely to comply with monitoring that does not require frequent pin (lancet) pricks for blood samples, and maintain better health as a result.
Google says that the lens, currently in prototype form, will use a wireless chip and a tiny glucose sensor planted between two layers of material designed for soft contact lenses to measure glucose levels in tears. The lens will use miniature lights to warn the diabetic person if their glucose readings reach a dangerous level. Google reports that they have “completed clinical research studies that explore tear/blood glucose correlation and test lens functionality and comfort.”
Dr. David Klonoff, medical director at the Diabetes Research Institute at Mills-Peninsula Health Services, worked with Google on a clinical study to evaluate that ability to detect glucose in tears. He was Principal Investigator and co-author of the protocol for the first study in the Google contact lens project.
“We measured tear glucose levels with a unique sampling system and a special measuring method that were developed by Google for very small volumes and very low glucose concentrations. We compared tear glucose levels with blood glucose levels to see how closely these two measurements tracked,” Dr. Klonoff explains.
Test results are still being analyzed by Dr. Klonoff’s team but he reports that he is optimistic about the outcomes and eventual benefit to patients.
“It was exciting working with scientists from Google and to collaborate with such a dynamic creative company. They do not let any barriers stand in their way. I have been following the work of the Google scientists for many years and they are extremely creative,” Dr. Klonoff says.
Read the official Google blog, Introducing Our Smart Contact Lens Project by Brian Otis and Babak Parviz, project co-founders.
He founded the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Health Services to facilitate development of new devices and drugs for people with diabetes. He has chaired the scientific advisory board for developing the first FDA-approved insulin patch pump and participated in development of the first FDA-approved dedicated diabetes telemedicine system, the first FDA-approved inhaled insulin, and the first three FDA-approved incretin drugs for diabetes. He recently published his findings in the New England Journal of Medicine as the lead investigator for the first-ever randomized controlled multicenter trial of the world’s first artificial pancreas product for outpatient use.
Replacements, Fusions and Transplants Heal Common and Chronic Injuries
New technologies developed in the last decade have helped ankle surgeons achieve better outcomes for a range of injuries and conditions.
The Mills-Peninsula Orthopedic Ankle Center team now offers total ankle replacement, a procedure that replaces a painful, arthritic joint with metal and plastic implants, similar to knee and hip replacements. Total ankle replacements are typically recommended for people who have advanced ankle arthritis, destroyed joint surfaces, or pain and stiffness that interferes with daily activities. Studies show that ankle replacements can safely and reliably ease pain and maintain mobility in patients. Improved ankle replacement parts made of metal and a smooth plastic material (polyethylene) can relieve the pain of bone rubbing against bone.
“As people get older, they’ve had more time to injure their ankles and joints,” says Todd Kim, M.D., a Mills-Peninsula orthopedic surgeon who has specialized training in both ankle and shoulder repairs.
The Mills-Peninsula Health Services Diabetes Research Institute in San Mateo, California, was the lead site and David C. Klonoff, M.D., was study chair of a national, multicenter study called ASPIRE (Automation to Simulate Pancreatic Insulin REsponse), an in-home clinical trial of the integrated MiniMed insulin pump with automatic insulin suspension, a feature called Threshold Suspend which is unique to MiniMed insulin pump systems. The trial was conducted at multiple investigational centers across the United States to determine the safety and efficacy of Threshold Suspend.
This clinical trial is the first, large in-home study to show the results of the integrated system when Threshold Suspend is incorporated. The trial compared two MiniMed sensor-augmented insulin pumps (integrated insulin pump with continuous glucose monitoring): one with the Threshold Suspend feature and one without.